Asset 1

Biotech

We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.

With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.

Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.

We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.

Life Sciences & Healthcare

OLG Frankfurt am Main: Abgabe von kostenlosen Arzneimittelmustern an Apotheker

13. Dezember 2022
Quick read

von Dr. Daniel Tietjen

Klicken Sie hier für Details
Life Sciences & Healthcare

EuGH: Anforderungen an die Voraussetzungen für das Umpacken von Arzneimitteln mit Blick auf die neuen Fälschungsschutzvorschriften

13. Dezember 2022
Briefing

von Dr. Daniel Tietjen

Klicken Sie hier für Details
Life Sciences & Healthcare

BGH: Berliner Verurteilungen wegen Handelstreibens mit CBD-Blüten rechtskräftig

13. Dezember 2022
Briefing

von Dr. Daniel Tietjen

Klicken Sie hier für Details
Life Sciences & Healthcare

BSG: Hohe Hürden für Cannabis auf Kassenrezept

13. Dezember 2022
Quick read

von Dr. Daniel Tietjen

Klicken Sie hier für Details

Events

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.